NEW YORK (dpa-AFX) – After a severe setback on Tuesday, the US stock exchanges started another attempt at recovery in the middle of the week. However, profits crumbled noticeably in the course of trading. Once again, concerns about the Coronavirus variant Omikron were widespread. News made the rounds that the confirmed Covid-19 cases in South Africa have almost doubled since Tuesday and that a first Omicron case has now also appeared in the USA. This virus variant has also been detected in the first cases in Great Britain, Switzerland, Norway and Brazil.
Omikron is currently classified as a matter of concern because of its rapid spread and numerous mutations. How ill the virus actually makes cannot yet be estimated due to the lack of sufficient data and since mainly young people have been infected so far.
Der Dow Jones Industrial
On the data side, the main focus was primarily on sentiment in US industry, which did not brighten as much as expected in November.
Among the individual values on the US stock exchanges were papers from vaccine manufacturers such as Biontech
The shares of Merck & Co
A cautious outlook broke the shares of the software manufacturer Salesforce
It was similar at the information technology company Hewlett Packard Enterprise
ISIN US2605661048 US6311011026
AXC0362 2021-12-01/20:03
Copyright dpa-AFX Wirtschaftsnachrichten GmbH. All rights reserved. Redistribution, republication or permanent storage without the express prior consent of dpa-AFX is not permitted.
– .